News archive
Showing 765 results
May 2021
-
Media Release
Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program
BEOVU (brolucizumab-dbll) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one… -
Media Release
Novartis commits to addressing racial disparities in breast cancer screening, treatment and care
-
Media Release
Novartis commits to addressing racial disparities in breast cancer screening, treatment and care
Black women with breast cancer are approximately 40% more likely to die compared to white women with breast cancer in the U.S.[1] - and are also more likely to be diagnosed at a later stage with… -
Story Hope
Addressing health inequities starts by looking within
The Novartis US Foundation has partnered with the Institute for Healthcare Improvement to help healthcare systems better serve patients.
-
Story Education and Awareness
At-home app helps patients stay engaged and adherent to vision monitoring remotely
Novartis begins U.S. pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely.
-
Media Release
Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media Release
Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
In KESTREL and KITE, BEOVU (brolucizumab-dbll) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in…
April 2021
-
Media Release
Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasis
At least 75% of children six years and older achieved PASI 90 at Week 52 when treated with Cosentyx in two pivotal studies1,2 Majority of children experienced improved health-related quality of… -
Media Release
Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS
Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients… -
Media Release
Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis
New post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently… -
Media Release
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
-
Media Release
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment EAST HANOVER, N.J., April 12, 2021…